⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 7, 2026Journal of Pediatric Gastroenterology and Nutrition

Is it time to consider oral vancomycin treatment for the management of pediatric inflammatory bowel disease irrespective of the presence of primary sclerosing cholangitis?

Marianne Samyn Marco Gasparetto

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to assess the viability of using oral vancomycin for pediatric inflammatory bowel disease management, regardless of liver complications.
Analysis of existing literature on oral vancomycin treatment efficacy.
Comparison of treatment outcomes in children with and without primary sclerosing cholangitis.
Indications that oral vancomycin may be beneficial in treating pediatric inflammatory bowel disease.
Results suggest effective management across different patient conditions.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Explores oral vancomycin effects on managing pediatric inflammatory bowel disease, suggesting broader application.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Samyn et al. (2026) studied this question.

synapsesocial.com/papers/69d8968f6c1944d70ce08176 https://doi.org/10.1002/jpn3.70431

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (<scp>PSC‐IBD</scp>): A matched analysis from the Paediatric <scp>PSC</scp> Consortium2024 · 43 citations
2Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease – paving a path forwardRCT · 2026 · 4 citations
3P1011Efficacy and safety of oral vancomycin therapy (OVT) in pre-liver transplant patients with PSC-IBD – A systematic review and meta-analysis of IBD outcomesMeta-Analysis · 2026
4Replies to comments on “proximally dominant inflammation at colonoscopy predicts pan-colonic histological remission following oral vancomycin therapy in pediatric ulcerative colitis”Original Research · 2026
5P0654Clinical and Endoscopic Outcomes of Oral Vancomycin (OVT) compared to Biologics in Primary Sclerosing Cholangitis associated with Inflammatory Bowel Disease (PSC-IBD): A Systematic Review and Bayesian Meta AnalysisMeta-Analysis · 2026

More related papers

P-480. Oral vancomycin prophylaxis to prevent recurrence of Clostridioides difficile infection in children with cancer2026
Oral vancomycin is not associated with meaningful changes in liver-related endpoints among adults with primary sclerosing cholangitis: A randomized, placebo-controlled trial2026
Secondary oral vancomycin prophylaxis and Clostridioides difficile infection in children and young adults with cancer: a retrospective cohort study2026

More from Journal of Pediatric Gastroenterology and Nutrition

Incidence and risk factors of parenteral nutrition‐associated cholestasis in surgical very low birth weight infantsWed,
Disease‐specific body composition patterns in children with cerebral palsy and spinal muscular atrophyWed,